Literature DB >> 28287385

Interference of direct oral anticoagulants in haemostasis assays: high potential for diagnostic false positives and false negatives.

Emmanuel J Favaloro1, Giuseppe Lippi2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28287385      PMCID： PMC5649956          DOI： 10.2450/2017.0301-16

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  19 in total

Review 1.  Laboratory testing of anticoagulants: the present and the future.

Authors:  Emmanuel J Favaloro; Giuseppe Lippi; Jerry Koutts
Journal:  Pathology       Date:  2011-12       Impact factor: 5.306

2.  Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; David D Gutterman; Holger J Schuünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.

Authors:  Roslyn Bonar; Emmanuel J Favaloro; Soma Mohammed; Leonardo Pasalic; John Sioufi; Katherine Marsden
Journal:  Pathology       Date:  2015-06       Impact factor: 5.306

Review 4.  Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?

Authors:  Giuseppe Lippi; Emmanuel J Favaloro
Journal:  Clin Chem Lab Med       Date:  2015-02       Impact factor: 3.694

Review 5.  The new or non-vitamin K antagonist oral anticoagulants: what have we learned since their debut.

Authors:  Brandon J McMahon; Hau C Kwaan
Journal:  Semin Thromb Hemost       Date:  2015-02-15       Impact factor: 4.180

6.  The effect of dabigatran on select specialty coagulation assays.

Authors:  Dorothy M Adcock; Robert Gosselin; Steve Kitchen; Denis M Dwyre
Journal:  Am J Clin Pathol       Date:  2013-01       Impact factor: 2.493

7.  A clinical audit of congenital thrombophilia investigation in tertiary practice.

Authors:  Emmanuel J Favaloro; Soma Mohammed; Nalini Pati; Man Yuk Ho; David McDonald
Journal:  Pathology       Date:  2011-04       Impact factor: 5.306

Review 8.  Laboratory investigation of thrombophilia: the good, the bad, and the ugly.

Authors:  Emmanuel J Favaloro; David McDonald; Giuseppe Lippi
Journal:  Semin Thromb Hemost       Date:  2009-10       Impact factor: 4.180

9.  Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests.

Authors:  Walter-Michael Halbmayer; Guenter Weigel; Peter Quehenberger; Josef Tomasits; Alexander C Haushofer; Gerold Aspoeck; Lorin Loacker; Mirjam Schnapka-Koepf; Georg Goebel; Andrea Griesmacher
Journal:  Clin Chem Lab Med       Date:  2012       Impact factor: 3.694

10.  The futility of thrombophilia testing.

Authors:  Emmanuel J Favaloro
Journal:  Clin Chem Lab Med       Date:  2014-04       Impact factor: 3.694
View more
  3 in total

1.  Hypercoagulable workup in a community hospital setting: to test or not to test; that is the question.

Authors:  Ashish Gupta; Poras Patel; Raheel Anwar; Diana Villanueva; Viswanath Vasudevan; Elizabeth Guevara
Journal:  J Community Hosp Intern Med Perspect       Date:  2019-11-01

2.  Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes.

Authors:  Hirosuke Yamaji; Takashi Murakami; Kazuyoshi Hina; Shunich Higashiya; Hiroshi Kawamura; Masaaki Murakami; Shigeshi Kamikawa; Satoshi Hirohata; Shozo Kusachi
Journal:  J Cardiovasc Electrophysiol       Date:  2019-11-12

3.  Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.

Authors:  L Slavik; J Jacova; D Friedecky; J Ulehlova; Z Tauber; J Prochazkova; A Hlusi; M Palova
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.